Quantcast

Adis Journals Embrace Open Access

April 4, 2011

BRIDGEWATER, N.J., April 4, 2011 /PRNewswire/ — Pharmacotherapy research is set to become vastly more accessible for all those who seek it. Wolters Kluwer Pharma Solutions, parent of the Adis family of medical journals and a leading provider of scientific information and analytics to professionals in the pharmaceutical and biotech fields, today announced it has added a new open access (OA) publishing option for authors submitting original research articles to the Adis line of pharmacology and pharmacotherapy journals — a total of 16 titles.

Adis content is subject to rigorous, independent peer review before publication, a practice that continues under the OA model. For more than 40 years, Adis journals were available only through pay-per-view or subscription. Effective today, researchers will increasingly have unrestricted, free access to a significant portion of content from new issues of these enduring, venerable titles. For existing subscribers this will be free, additional content.

Popular journals in the high-impact portfolio include: Clinical Pharmacokinetics, CNS Drugs, Drug Safety, and Adis’ flagship title, Drugs, which holds an impact factor of 4.732. Under the new guidelines, OA articles are published online-only, and are accessible on AdisOnline and Ovid to read, copy, share and distribute for non-commercial purposes.

Last June, the company successfully transitioned Drugs in R&D from subscription-only to fully OA, making it the first Adis journal to offer OA delivery.

“The Drugs in R&D transition helped pave the way for an open access option across all of the Adis journals,” said Iain Spray, Global Product Manager for Adis, Wolters Kluwer Pharma Solutions. “Under our new publishing policy, the author can opt at time of submission to have an accepted article published under a traditional or open access license. We expect many will gravitate to the open option as it tends to generate more article views and citations.”

The OA format has been widely adopted by STM publishers in recent years as the model for new start-up journals, partly in response to market demand and partly due to the increasing difficult challenge of developing an audience of paid subscribers for a new title in a saturated marketplace. These new journals have been popular with authors who want to see their research made available as widely as possible, but increasingly they also demand an OA publishing option for recognized, high-impact journals with established readership.

“Unlike the majority of open access journals, most Adis journals have a regular readership, good impact factors and MEDLINE indexing,” continued Spray. “It is in response to popular demand that Adis journals now offer authors the open access option alongside the traditional option. From a subscriber perspective this is all additional, free content on top of the content they pay for.”

Opens Door to Rapid Publishing

OA publishing is traditionally associated with the ability to get peer-reviewed research results into the public domain very quickly. With Adis journals this can be made even quicker for authors who select the optional Adis Rapid Publication Service, enabling publication of new research in as little as three to four weeks from submission.

The Adis peer-review process and acceptance criteria apply to OA articles in exactly the same way as to articles submitted in the traditional way. If an OA or Rapid Publication Service option is selected, the journal editor is “blinded” during the acceptance process to remove any potential commercial bias.

“The greatest value of Adis journals to the reader is that as a portfolio of titles they offer a one-stop shop for a program of comprehensive reviews and cutting-edge original research articles on all aspects of pharmacology and pharmacotherapy, much like a constantly updating textbook,” added Spray. “By offering this service, we are seeking to expand the body of original research in our journals, in a way that is widely accessible and beneficial for all concerned.”

For access, visit AdisOnline.com or for more information, visit the company’s website at www.wolterskluwerpharma.com.

About Wolters Kluwer Pharma Solutions

Wolters Kluwer Pharma Solutions, Inc. (Bridgewater, NJ) is a leading provider of information and analytics to the pharmaceutical, biotech, and medical device industries. The company’s brands include Adis, Source® and Lippincott Williams & Wilkins. A provider of business intelligence and services, Adis publishes 19 peer-reviewed drug research journals and 2 newsletters and offers the most respected drug and clinical trials databases in the pharma industry. Lippincott Williams & Wilkins (LWW) is a leading international healthcare publisher with nearly 300 periodicals and 1,500 books in more than 100 disciplines. A longstanding provider of market data and healthcare analytics, Source® offers a unique set of comprehensive patient and physician-level prescribing and usage data. For more information, visit www.wolterskluwerpharma.com.

The company is a wholly owned subsidiary of Wolters Kluwer, U.S., part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer’s leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer has 2010 annual revenues of euro 3.6 billion ($4.7 billion), employs approximately 18,200 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.

Contact:
Tom Kivett
Kivett & Company Communications
+1 212 727-2935
tkivett@kivettandco.com

SOURCE Wolters Kluwer Pharma Solutions


Source: newswire



comments powered by Disqus